H.R. 1462 would authorize the Department of Health and Human Services (HHS) to plan and coordinate activities related to prenatal opioid abuse and neonatal abstinence syndrome (NAS). In addition, this bill would require the Centers for Disease Control and Prevention (CDC) to expand data collection and surveillance activities and would require the Agency for Healthcare Research and Quality (AHRQ) to study and recommend treatments for prenatal opioid abuse and NAS.
CBO estimates that implementing H.R. 1462 would cost $27 million over the 2016-2020 period, assuming appropriation of the necessary amounts. Enacting H.R. 1462 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
H.R. 1462 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.
